By continuing to browse this site, you agree to the use of cookies to enhance your user experience:
read our legal notice and privacy policy.

I understood
 
 
Centre de Cancérologie de la Porte de Saint-Cloud
  •  
Homepage  /   Quality and safety  /
The oncology center
Presentation and history Quality and safety Testimonials Organisation chart HR policy and recruitment Key figures and indicators
The medical team
Presentation of the medical team A tailored approach to cancer care Coordination with your GP Making an appointment
The treatments
Organisation of oncology care Radiotherapy Gyroscopic radiosurgery Chemotherapy Medical oncology hospitalisation Glossary
Patient support
Announcing the diagnosis Special paramedical consultation Pain management Nutritional consultation Psychological consultation Social welfare Beauty advisor
Practical information
How to find us Your admission Your stay Going home Medical factsheets
Networks and partners The Cancer Care initiative Research and publications
Contacts

Click on a department in the list below to send
an e-mail directly to the service required...

Center switchboard Reception, admissions, appointments
Radiotherapy Chemotherapy Medical hospitalisation Pharmacy
Service users’ representative
For any medical question

... or click here to access
the nominative list of contacts

Policy for quality and risk management

Doctors and other staff members at the “Centre de Cancérologie de la Porte de Saint-Cloud” are committed to providing each patient with high quality treatments in maximum safety and with tailored healthcare based on meaningful human relationships.

This approach has been recognized through certification in 2011, without reservation or advisement, by the Haute Authorité de Santé [HAS], which oversees quality and healthcare in French hospitals.

You can read these certification reports on the HAS Internet website: www.has-sante.fr

Today, the “Centre de Cancérologie de la Porte de Saint-Cloud” continues its policy of excellence with the full integration of the radiotherapy hub and medication circuit in its quality and risk management system.

Entities dealing with quality and treatment safety

1. The Establishment’s Medical Commission (CME) which validates annual targets for deploying the quality and risk management policy


2. A Quality Steering Committee / department managers

It is composed of all department managers (representative from radiotherapy, hospitalisation, radiophysics, pharmacy, admissions, and administration departments), meeting every month to develop quality and treatment safety in every sector.

The Quality Steering Committee meets at least every month and sometimes more often, depending on the projects underway; it ensures the management of ongoing quality improvement within the scope of its missions to:

  • Define Quality Assurance priorities (audits, assessments) and coordinate actions to be implemented.
  • Ensure management of HAS Certification process with allocation of themes per manager
  • Ensure the coordination and monitoring of action plans
  • Organise the setting up of working groups
  • Validate all the steps and processes


3. COVIRIS


3.1 This committee is tasked with defining priorities with regards to risk management and coordinating the different resources involved in the prevention and management of risks:

  • Patient risks (major risks linked to treatments)
  • Establishment risks (linked to equipment, infrastructure, etc.)
  • Professional risks


3.2 Its operation is based on:

  • a specific consultant, Dr. Assouline, who provides information and coordinates the management of clinical risks for patients as well as heading the management of the medical staff.
  • monthly meetings to ensure that declarations of undesirable events are processed.
  • CREX: permenant working groups in radiotherapy and medication circuit which meets every two months.
  • the Mortality and Morbidity Review: set up for hospitalisation in 2010, in addition to the CREX.


3.3 Priorities defined by COVIRIS:

  • Make the medication circuit secure
  • Make computerised patient files secure
  • Reinforce patient identity vigilance, especially in radiotherapy
  • Promote a culture of treatment safety
  • Monitor indicators and dashboards


4. Coordination

Coordination between the Steering Committee and COVIRIS is ensured by a core of professionals participating in both committees who are involved in the development of quality and management policy.

Coordination is also ensured with the CME for managing EPP processes under the supervision of the Chairman of the CME, who deploys evaluations of professional practices in every Clinic sector in line with the quality and risk management programme.

Different aspects of quality management have been assigned to managers sitting on the Steering Committee who are tasked to work with their teams and resource persons on the identification of risks and feeding the quality account which is validated by the Executive Committee and the CME.

Quality and treatment safety objectives

The Center’s quality and treatment safety policy is defined around 5 development priorities:

  1. Organise, steer and coordinate Quality and Treatment Safety management based on the process management and ISO Certification. This especially includes coordination of healthcare vigilance and monitoring undesirable events, FSEI, CREX and patient complaints by involving service users in these processes.
  2. Computerising document management: Updating procedures with regards to frames of reference for best practices.
  3. Communicating and handling information: ensure that quality procedures are generally adopted and that each professional embraces the policy by developing a culture of treatment safety.
  4. Encourage the policy for evaluations of professional practices
    The “Centre de Cancérologie de la Porte de Saint-Cloud” has integrated its procedures for the Evaluation of Professional Practices (EPP) in its quality and treatment safety policy. It is also taken into account in treatment and medical projects.
    The EPP programme is discussed and validated by the extended CME under the aegis of the CME Chairman, selected as the EPP correspondent. The choice of EPPs takes into account strategic guidelines, PAQSS (programmes for quality and treatment safety actions), the concerns of professionals with regard to quality and patient safety, and requirements of the HAS, INCA and ASN, etc.
  5. Draw up, implement and monitor the annual quality improvement programme through an efficient, dashboard driven policy. This process can be part of a Benchmarking approach with other structures.

Policy and organisation for the Evaluation of Professional Practices (EPP)

The choice of EPP themes reflects the Center’s desire to deploy evaluations in all activity sectors and for healthcare and specific practices at the establishment as well as meeting the requirements of supervisory bodies: ARS, INCA, HAS, etc.

A medical manager was appointed for each EPP. Depending on the theme, different professionals joined in to successfully complete these evaluations.

The Chairman of the CME is designated as the EPP correspondent. He ensures the coordination and monitoring of processes undertaking in association with colleagues for medical EPPS and with the health executive in medical oncology and chemotherapy and the radiotherapy executive for paramedical EPPs.

The state of progress is regularly monitored and reported back to the Steering Committee and EPP correspondent. Re-evaluation is made according to studies carried out or scheduled in the aim of measuring the impact of improvement actions ensuing from various implemented studies.

Clinical practice indicators are integrated in the EPP programme and will be reinforced with the development of dashboards at the “Centre de Cancérologie de la Porte de Saint-Cloud”.

Information is given to professionals via a letter, or by the institutional bodies or through their participation in working groups. Depending of the state of progress of each study, the results are then disseminated.

EPP development strategy is reviewed every year by the CME in line with challenges faced by the Center and issues regarding the patient experience.

Directions   I   Legal Notice
Centre de Cancérologie de la Porte de Saint-Cloud - 30, rue de Paris, 92100 Boulogne-Billancourt       Tel. +33 1 41 10 27 27
© 2026 Centre de Cancérologie de la Porte de Saint-Cloud   /   Last updated 04-24, 2026   /   Webdesign & Photos credit: Mediaction, Paris - Powered by doxFinder™